Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer: A systematic review and meta-analysis

• Published in: Current urology Vol. 19; no. 3; pp. 157 - 167
• Main Authors: He, Xiaohui, Huang, Shibo, Jiang, Qiuhong, Huang, Conghui, Huang, Weisheng, Liang, Weiming
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01.05.2025; Wolters Kluwer Health
• Subjects: Reviews; Programmed death-ligand 1 inhibitor; Programmed cell death protein 1; Urothelial carcinoma; Immune-checkpoint inhibitor

Abstract Background Recent clinical trials have shown that inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (programmed cell death-ligand 1 [PD-L1]) provide significant efficacy and clinical benefit in the treatment of advanced or metastatic urothelial carcinoma (UC). This s...